REMARKS

After entry of this paper claims 1-3, 5-14 and 46-61 are pending. Claims 58-61 are new.

Amendments to the specification correct typographical and other errors.

Support for the claims is found throughout the disclosure with exemplary support as follows. Support for claims 46-50 and 53 is at least at page 88, lines 11-22 and page 326, lines 29-34 (R^4 moieties, e.g., $-NH_2$ or ester, and their configurations), page 53, line 32, through page 54, line 5 (hydrogen atom configurations), page 326, lines 11-16 (R^1 moieties, e.g., -OH, and their configurations) and page 163, lines 23-24 (amide and carbamate protecting groups). Support for claim 51 is at least at page 327, lines 27-29 (subject is a mammal). Support for claims 52 and 54 is at least at original claim 6 (neutropenia) and page 240, lines 29-34. Support for humans and non-human primates recited in new claims 58 and 60 is at least at paragraph 458.

Other papers of record include the declaration by Dr. Reading that Applicants filed on January 17, 2006 in response to the office action mailed on July 14, 2005. The declaration discusses treatment of blood cell deficiencies that were induced by exposure to radiation or a chemotherapy agent such as carboplatin. Administration of 3β-hydroxy-17β-aminoandrost-5-ene and several compounds resulted in amelioration of deficiencies including neutropenia thrombocytopenia and anemia.

Applicants direct the Office's attention to the teaching in the application, including (1) example 38 beginning at paragraph 1270, which provides detailed protocols for modulating hematopoiesis, (2) examples 39 and 40 beginning at paragraphs 1283 and 1293, which provide detailed human clinical protocols for use of compounds, (3) the specification beginning at paragraph 602, which provides detailed discussion of methods to make, prepare and use formulations that contain the compounds, and (4) the specification beginning at paragraph 602, which provides detailed discussion of treatments for blood cell deficiencies.